首頁 > 抗體/蛋白 > 藥物對照抗體

瀏覽量: 148

產(chǎn)品名稱： Research Grade Lumiliximab ( 魯昔單抗 )
產(chǎn)品貨號： CSD00086
貨期： 現(xiàn)貨
價格與訂購： 2480
數(shù)量：

庫存： 100
規(guī)格： 100μg

產(chǎn)品信息
如何訂購

貨號（Catalog No.）

CSD00086

通用名INN

Lumiliximab

純度(Purity)

>95%

濃度( Concentration)

1mg/ml

Formulation

PBS buffer PH7.5

Source

CHO cells

內(nèi)毒素(Endotoxin level)

Please contact with the lab for this information.

產(chǎn)品描述(Description)

Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody,for the potential treatment of allergic conditions.Lumiliximab was developed by IDEC Pharmaceuticals,which was acquired by Biogen.Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23,a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells.CD23, also known as Fc epsilon RII,or FcεRII,is the "low affinity" receptor for IgE, an antibody isotype involved in allergy and resistance to parasites and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells,activated macrophages, eosinophils, follicular dendritic cells and platelets.

別名(Alternative names)

IDEC-152,P5E8

靶點;物種(Specificity target name;species)

FCER2[Homo sapiens]

種類(Species)

Chimeric

受體鑒定(Receptor identification)

IgG1-kappa

分子量(MV)

47750.00 Da

CAS

357613-86-6